Morning all-adding to observations the line in the report that tickled my fancy was
"Paradigm’s focus will now shift to the initiation and recruitment of Australian patients with Knee OA for,PARA-008 which will evaluate biomarkers in PPS treated subjects, and the Pivotal Phase 3 clinical trials for drug registration."
Almost ironic that the phase 3 trial results is an afterthought.
Ann: Consistent pain reduction and improvement in function data, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
43.0¢ |
Change
0.010(2.38%) |
Mkt cap ! $166.9M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 43.0¢ | 42.0¢ | $73.21K | 171.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 68680 | 42.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.0¢ | 21767 | 3 |
View Market Depth
| Last trade - 10.22am 23/07/2025 (20 minute delay) ? |
| PAR (ASX) Chart |